Cargando…

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence

Tyrosine kinase inhibitor (TKI) use is critical in the care of patients with chronic myeloid leukemia (CML). Quantitative polymerase chain reaction (qPCR) testing for BCR-ABL1 every 3 months during the first year of TKI treatment is recommended to assure achievement of milestone response goals. Real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shallis, Rory M., Wang, Rong, Zeidan, Amer M., Huntington, Scott F., Neparidze, Natalia, Stempel, Jessica M., Mendez, Lourdes M., Di, Mengyang, Ma, Xiaomei, Podoltsev, Nikolai A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Health Services and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338212/ https://www.ncbi.nlm.nih.gov/pubmed/36939371 http://dx.doi.org/10.1182/bloodadvances.2022009074

Ejemplares similares

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
por: Wang, Rong, et al.
Publicado: (2022)

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021)

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Shallis, Rory M., et al.
Publicado: (2021)

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
por: Podoltsev, Nikolai A., et al.
Publicado: (2023)

Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period
por: Neparidze, Natalia, et al.
Publicado: (2022)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2023)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes
por: LoCastro, Marissa, et al.
Publicado: (2021)

Code status transitions in patients with high-risk acute myeloid leukemia
por: Abrams, Hannah R., et al.
Publicado: (2022)

Alcohol Septal Ablation after Suboptimal Surgical Septal Myomectomy
por: Cherif, Ehab, et al.
Publicado: (2018)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
por: Zeidan, Amer M., et al.
Publicado: (2017)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
por: Johnson, Kate M., et al.
Publicado: (2022)

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals
por: Singh, Ashima, et al.
Publicado: (2021)

Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)

Preliminary construct validity of patient-reported outcomes to assess chronic pain in adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2023)

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines
por: Nieuwlaat, Robby, et al.
Publicado: (2021)

Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy
por: Cronin, Robert M., et al.
Publicado: (2022)

ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology
por: Wood, William A., et al.
Publicado: (2021)

Coping in caregivers of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support
por: Lee, Alfred Ian, et al.
Publicado: (2022)

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)

Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
por: Lee, Thomas D., et al.
Publicado: (2023)

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
por: Hantel, Andrew, et al.
Publicado: (2021)

Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists
por: Stojkov, Igor, et al.
Publicado: (2021)

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
por: Chien, Kelly S., et al.
Publicado: (2023)

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
por: Luan, Danny, et al.
Publicado: (2022)

What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients
por: Barata, Anna, et al.
Publicado: (2023)

Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study
por: Bankar, Aniket, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q8rjlhraojrbamu6f97vaa1s5e